Barely Significant
← all excerpts

Abandon ifosfamide-based regimen and use paclitaxel-carboplatin regimen for the treatment of uterine carcinosarcoma.

J Chin Med Assoc · 2022 · PMC12755637 · PMID 35385437

Europe PMCDOI
1
hedged sentence
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)
4 Although the statistical analysis about measuring OS failed to reach the significance, patients treated with paclitaxel-platinum regimen still showed a trend of the longer median OS than ifosfamide-platinum regimen did (28.7 months versus 9.5 months, p = 0.06). 4 Because only 16 patients were enrolled in our study, we cannot make a strong conclusion to recommend that using paclitaxel-platinum regimen for the treatment of advanced UCS patients may be a b

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.